Mark has 30 years of experience leading successful drug commercialization efforts as a pharmaceutical executive, with a focus on therapies for central nervous system (CNS) disorders.
— Sachs Associates (@SachsAssociates) August 18, 2020
e-Meet Mark at #Sachs_BEF
More info @ https://t.co/XI3zEYGyl2@ArvelleTx pic.twitter.com/qz9Ka2oeWb
